RxDoctor Payments Data

Stephanie Young, DO

Family Medicine · Ebensburg, PANPI 1285604561

Payments from drug & device makers

$391in general payments, 2019–2025

Across 23 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$114
  • Pfizer$81
  • GSK$54
  • Lilly USA, LLC$47
  • AstraZeneca$34
  • Exact Sciences$31
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$391100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk7$114
Pfizer4$81
GSK3$54
Lilly USA, LLC3$47
AstraZeneca2$34
Exact Sciences2$31
Amgen1$17
AbbVie1$13

How this compares

$391 in reported general payments places this provider in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$29,272
Medicare patients
90
Services billed
566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$54,983
EliquisApixaban42$40,402
FarxigaDapagliflozin Propanediol14$15,288
MyrbetriqMirabegron18$13,625
LinzessLinaclotide11$11,727
XareltoRivaroxaban16$11,565
Atorvastatin Calcium424$7,500
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,850
Pantoprazole Sodium171$3,273
Levothyroxine Sodium259$3,172
Rosuvastatin Calcium91$2,529
Gabapentin128$2,092
Tolterodine Tartrate ErTolterodine Tartrate21$2,016
Potassium Chloride61$1,969
Amlodipine Besylate212$1,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$114$54,98356 claims
PfizerEliquis$81$40,40242 claims
AstraZenecaFarxiga$34$15,28814 claims
AbbVieLinzess, Synthroid$13$13,56152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Ebensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →